These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38759301)

  • 1. Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation.
    May CK; Noble PW; Herzog EL; Meffre E; Hansen JE
    Biochem Biophys Res Commun; 2024 Aug; 720():150123. PubMed ID: 38759301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais.
    Foocharoen C; Watcharenwong P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
    Int J Rheum Dis; 2017 Oct; 20(10):1572-1581. PubMed ID: 28296274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific autoantibody profiles and disease subgroups correlate with circulating micro-RNA in systemic sclerosis.
    Wuttge DM; Carlsen AL; Teku G; Steen SO; Wildt M; Vihinen M; Hesselstrand R; Heegaard NH
    Rheumatology (Oxford); 2015 Nov; 54(11):2100-7. PubMed ID: 26163687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: a promising surveillance marker of therapy?
    Moazedi-Fuerst FC; Kielhauser SM; Hermann J; Meilinger M; Demel U; Stradner MH; Graninger WB
    Scand J Rheumatol; 2015; 44(6):519-20. PubMed ID: 26376839
    [No Abstract]   [Full Text] [Related]  

  • 5. Autoantibodies to topoisomerase I in a patient with systemic lupus erythematosus without features of scleroderma.
    Stojanov L; Satoh M; Dooley MA; Kuwana M; Jennette JC; Reeves WH
    Lupus; 1995 Aug; 4(4):314-7. PubMed ID: 8528230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Frequency of Activated Switched Memory B Cells and Its Association With the Presence of Pulmonary Fibrosis in Diffuse Cutaneous Systemic Sclerosis Patients.
    Simon D; Balogh P; Erdő-Bonyár S; Böröcz K; Minier T; Czirják L; Berki T
    Front Immunol; 2021; 12():686483. PubMed ID: 34276673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis.
    Clark KEN; Campochiaro C; Csomor E; Taylor A; Nevin K; Galwey N; Morse MA; Singh J; Teo YV; Ong VH; Derrett-Smith E; Wisniacki N; Flint SM; Denton CP
    Ann Rheum Dis; 2021 Dec; 80(12):1584-1593. PubMed ID: 34230031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects.
    Pourquier P; Pilon AA; Kohlhagen G; Mazumder A; Sharma A; Pommier Y
    J Biol Chem; 1997 Oct; 272(42):26441-7. PubMed ID: 9334220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
    Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
    Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.
    Grassegger A; Pohla-Gubo G; Frauscher M; Hintner H
    Wien Med Wochenschr; 2008; 158(1-2):19-28. PubMed ID: 18286246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups.
    Clark KEN; Xu S; Attah M; Ong VH; Buckley CD; Denton CP
    Ann Rheum Dis; 2023 Dec; 82(12):1568-1579. PubMed ID: 37580109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diversity of DNA topoisomerases I and inhibitors.
    Pommier Y
    Biochimie; 1998 Mar; 80(3):255-70. PubMed ID: 9615865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Topoisomerase I mutations are associated with resistance to camptothecin.
    Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
    Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I.
    Pourquier P; Ueng LM; Kohlhagen G; Mazumder A; Gupta M; Kohn KW; Pommier Y
    J Biol Chem; 1997 Mar; 272(12):7792-6. PubMed ID: 9065442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
    Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
    Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I.
    Guldner HH; Szostecki C; Vosberg HP; Lakomek HJ; Penner E; Bautz FA
    Chromosoma; 1986; 94(2):132-8. PubMed ID: 2428564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase I in Human Disease Pathogenesis and Treatments.
    Li M; Liu Y
    Genomics Proteomics Bioinformatics; 2016 Jun; 14(3):166-171. PubMed ID: 27181710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis.
    Mehta H; Goulet PO; Nguyen V; Pérez G; Koenig M; Senécal JL; Sarfati M
    Autoimmunity; 2016 Dec; 49(8):503-513. PubMed ID: 27808577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-emergence of anti-topoisomerase I antibody with exacerbated development of skin sclerosis in a patient with systemic sclerosis.
    Hamaguchi Y; Fujimoto M; Hasegawa M; Matsushita T; Takehara K
    J Am Acad Dermatol; 2010 Jan; 62(1):142-144. PubMed ID: 19733937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
    Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
    BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.